a collection of information unless it contains a valid OMB control number.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10599446	
Filing Date		2006-09-26	
First Named Inventor Yoshi		inori MORIYAMA	
Art Unit		NONE	
Examiner Name	Not Y	et Assigned	
Attorney Docket Number		Q97450	

				U.S.	PATENTS		Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant			ines where es or Relevant
	1	6284243	B1	2001-09-04	Masuyama, et al.			
	2	6235719	B1	2001-05-22	Harang			
	3 6534304 B1 2003-03-18 Yamamoto, et al.							
	4	6444203	B2	2002-09-03	Krueger, et al.			
	5	5449683		1995-09-12	Wurtman			
If you wis	h to a	dd additional U.S. Paten		р.	ease click the Add button.		Add	
U.S.PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document Pages, Columns, Lines Relevant Passages or Figures Appear			
	1	20040097714	A1	2004-05-20	Maubois, et al.			

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10599446		
Filing Date		2006-09-26		
First Named Inventor Yoshi		nori MORIYAMA		
Art Unit		NONE		
Examiner Name Not You		et Assigned		
Attorney Docket Number		Q97450		

	2	20050074500	A1	2005-04	1-07	Kitamura, et al					
If you wis	h to a	dd additional U.S. Publ	ished Ap	plication	citatio	n information p	lease click the Add	buttor	Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>		Name of Patentee Applicant of cited Document	or	where Re	or Relevant	тя
	1										
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	button	Add		
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Cite No							Тs			
	1	Seij TSUBOI et al.; "Hakkomju Whey Toyo ni yoru Rat Shokatarchu Melatorin Gosel eno Eikyo", Nippon Yakugakukai Nerikai Koen Yoshishu, 05 March, 2005 (05.03.05), vol. 125, No. 3, P.4330-0148									
	2	HEINE, W. et al., "THE SIGNIFICANCE OF TRYPOTOPHAN IN HUMAN NUTRITION", AMINO ACID, (1995), Vol. 9, pages 191 to 195, full text, SUMMARY, FIG 1, page 200, 10th line from the bottom to page 201, line 26									
If you wis	h to a	dd additional non-pater	t literatu	re docu	ment cit	tation informati	on please click the	Add b	utton A	dd	
				EX	AMINE	R SIGNATUR	E				
Examiner	Signa	ture					Date Conside	red			
		itial if reference consid						P 609.	Draw line	through a	

See Kint Codes of USPTO Patent Documents at www.ISPTO.QDV or MFPP 90104. Enter doins that isseed the document, by the two-letter code (WIPO) Standard ST3.) For Lipiances petant for counters, the inclusion of the year of the region of the Emporer many precede the serial runber of the patent document. If kind of counters by the appropriate symbols as andicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if Emploit burguages threatistics and attached.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10599446		
Filing Date		2006-09-26		
First Named Inventor Yoshi		nori MORIYAMA		
Art Unit		NONE		
Examiner Name Not Y		et Assigned		
Attorney Docket Numb	ec	Q97450		

#### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make	the appropriate	selection(s):
---------------	----------	------------------	-----------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/97(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Peter D. Olexy

▼ None

Name/Print

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Registration Number

24.513

Tomas or and origination			
Signature	/Peter D. Olexy/	Date (YYYY-MM-DD)	2006-11-02

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandri, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.